Bibliotecas PUC-SP - Busca Integrada

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

nork Maarten J. Deenen, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens
Argitaratua izan da Therapeutic Advances in Medical Oncology (2013-01-01)

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis

nork Anke E. Kip, Monique Wasunna, Fabiana Alves, Jan H. M. Schellens, Jan H. M. Schellens, Jos H. Beijnen, Jos H. Beijnen, Jos H. Beijnen, Ahmed M. Musa, Eltahir A. G. Khalil, Thomas P. C. Dorlo
Argitaratua izan da Frontiers in Cellular and Infection Microbiology (2018-06-01)

Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar

nork Emilia Sawicki, Michel J. Hillebrand, Hilde Rosing, Jan H.M. Schellens, Bastiaan Nuijen, Jos H. Beijnen
Argitaratua izan da Journal of Pharmaceutical Analysis (2016-08-01)

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer

nork Marie-Rose B.S. Crombag, Markus Joerger, Beat Thürlimann, Jan H.M. Schellens, Jos H. Beijnen, Alwin D.R. Huitema
Argitaratua izan da Cancers (2016-01-01)

Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy

nork J. G. Coen van Hasselt, Karel Allegaert, Kristel van Calsteren, Jos H. Beijnen, Jan H. M. Schellens, Alwin D. R. Huitema
Argitaratua 2014-01-01

Corrigendum to “Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy”

nork J. G. Coen van Hasselt, Karel Allegaert, Kristel van Calsteren, Jos H. Beijnen, Jan H. M. Schellens, Alwin D. R. Huitema
Argitaratua 2015-01-01

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple <i>DPYD</i> Variants

nork Carin A. T. C. Lunenburg, Linda M. Henricks, André B. P. van Kuilenburg, Ron H. J. Mathijssen, Jan H. M. Schellens, Hans Gelderblom, Henk-Jan Guchelaar, Jesse J. Swen
Argitaratua izan da Genes (2018-11-01)

Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis

nork Bart A.W. Jacobs, Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels deVries, Didier Meulendijks, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema
Argitaratua izan da CPT: Pharmacometrics & Systems Pharmacology (2019-12-01)

Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort

nork Aurelia H. M. deVries Schultink, Marie‐Rose B. S. Crombag, Erik vanWerkhoven, Hans‐Martin Otten, Andre M. Bergman, Jan H. M. Schellens, Alwin D. R. Huitema, Jos H. Beijnen
Argitaratua izan da Cancer Medicine (2019-04-01)

Detection of Colorectal Cancer by Serum and Tissue Protein Profiling: A Prospective Study in a Population at Risk

nork Judith Y.M.N. Engwegen, Annekatrien C.T.M. Depla, Annemieke Cats, Henriëtte Tuynman, Henk A. van Heukelem, Pleun Snel, Wouter Meuleman, Lodewyk Wessels, Jan H.M. Schellens, Jos H. Beijnen
Argitaratua izan da Biomarker Insights (2008-01-01)

No relation between docetaxel administration route and high‐grade diarrhea incidence

nork Jeroen J. M. A. Hendrikx, Frederik E. Stuurman, Ji‐Ying Song, Vincent A. deWeger, Jurjen S. Lagas, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel, Jan H. M. Schellens, Serena Marchetti
Argitaratua izan da Pharmacology Research & Perspectives (2020-08-01)

Detection of Colorectal Cancer by Serum and Tissue Protein Profiling: A Prospective Study in a Population at Risk

nork Judith Y.M.N. Engwegen, Annekatrien C.T.M. Depla, Marianne E. Smits, Annemieke Cats, Henriëtte Tuynman, Henk A. Van Heukelem, Pleun Snel, Wouter Meuleman, Lodewyk F. Wessels, Jan H.M. Schellens, Jos H. Beijnen
Argitaratua izan da Biomarker Insights (2008-01-01)

Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors

nork Daphne W. M. Voogd, Merel J. J. Lucassen, Ruud van der Noll, Sybrand W. J. Zielhuis, David Boss, Jos H. Beijnen, Hilde Rosing, Matthijs Tibben, Alwin D. R. Huitema, Jan H. M. Schellens, Neeltje Steeghs
Argitaratua izan da Oncology and Therapy (2025-05-01)

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine

nork Femke M. de Man, G.D. Marijn Veerman, Esther Oomen-de Hoop, Maarten J. Deenen, Didier Meulendijks, Caroline M.P.W. Mandigers, Marcel Soesan, Jan H.M. Schellens, Esther van Meerten, Teun van Gelder, Ron H.J. Mathijssen
Argitaratua izan da Therapeutic Advances in Medical Oncology (2019-04-01)

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

nork Hans Gelderblom, Patrick M Forde, Aung Naing, Matthew Taylor, Jennifer Mataraza, Marcus O Butler, Todd M Bauer, Justin F Gainor, Chia-Chi Lin, Sunil Sharma, Maria Ochoa de Olza, Andrea Varga, Jan H M Schellens, Hongqian Wu, Haiying Sun, Antonio P Silva, Jason Faris, Scott Cameron
Argitaratua izan da Journal for ImmunoTherapy of Cancer (2020-05-01)

A phosphotyrosine switch regulates organic cation transporters

nork Jason A. Sprowl, Su Sien Ong, Alice A. Gibson, Shuiying Hu, Guoqing Du, Wenwei Lin, Lie Li, Shashank Bharill, Rachel A. Ness, Adrian Stecula, Steven M. Offer, Robert B. Diasio, Anne T. Nies, Matthias Schwab, Guido Cavaletti, Eberhard Schlatter, Giuliano Ciarimboli, Jan H. M. Schellens, Ehud Y. Isacoff, Andrej Sali, Taosheng Chen, Sharyn D. Baker, Alex Sparreboom, Navjotsingh Pabla
Argitaratua izan da Nature Communications (2016-03-01)

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

nork Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore
Argitaratua izan da Journal for ImmunoTherapy of Cancer (2023-03-01)

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD

nork Jonathan E. Knikman, Qinglian Zhai, Carin A. T. C. Lunenburg, Linda M. Henricks, Stefan Böhringer, Maaike van der Lee, Femke M. de Man, Steven M. Offer, Shikshya Shrestha, Geert-Jan Creemers, Arnold Baars, Vincent O. Dezentjé, Alexander L. T. Imholz, Frank J. F. Jeurissen, Johanna E. A. Portielje, Rob L. H. Jansen, Paul Hamberg, Helga J. Droogendijk, Miriam Koopman, Peter Nieboer, Marlène H. W. van de Poel, Caroline M. P. W. Mandigers, Ron H. N. van Schaik, Hans Gelderblom, Ron H. J. Mathijssen, Jan H. M. Schellens, Annemieke Cats, Henk-Jan Guchelaar, Jesse J. Swen
Argitaratua izan da Genome Medicine (2024-08-01)